



medibio

ASX:MEB

INVESTOR PRESENTATION

MAY 2022

FORWARD LOOKING STATEMENTS

Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Medibio Limited and should not be relied upon as an independent source of information. Please contact Medibio Limited and/or refer to the Company's website for further information. The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified.

None of Medibio Limited, or any of its affiliates or associated companies (or any of their officers, employees, contractors or agents (the Relevant Persons)) makes any representation or warranty as to the accuracy, completeness or reliability of the information, or the likelihood of fulfilment of any forward-looking statement or any outcomes expressed or implied in any forward-looking statements.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Medibio Limited's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks.

The purpose of the presentation is to provide an update of the business of **Medibio Limited (ASX:MEB)**. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification.

Actual results could differ materially to the assumptions made and Medibio Limited's current intentions, plans, expectations and beliefs about the future. You are urged to view all forward looking statements contained in this presentation with caution. Except as required by applicable law or the ASX listing rules, the Relevant Persons disclaim any obligation or undertaking to publicly update any statements in this presentation, whether as a result of new information or future events.

This presentation should not be relied on as a recommendation or forecast by Medibio Limited. This presentation does not constitute investment advice or should be construed as either an offer to sell, or a solicitation of an offer, to buy or sell shares in any jurisdiction.

New US-based IR Firm Appointed

RBMG™

www.rbmilestone.com

Medibio Limited is pleased to announce that it has retained the United States based investor relations firm, RB Milestone Group LLC (“RBMG”), for an initial period of twelve months which started in February 2022. RBMG will be providing corporate communications advisory, non-deal roadshow advisory, market intelligence advisory, and business referrals to the management team of Medibio.

Medibio’s Founder and Managing Director, Claude Solitario, stated:

“Medibio remains focused on advancing towards becoming one of the first companies with a regulated screening technology for mental health. RBMG has an excellent track record of targeting the right investor groups. We look forward to working with RBMG which will be leveraging its long-standing relationships to ensure that our narrative is communicated effectively to a US audience that is very receptive to mental health solutions, particularly considering the effects of COVID on mental health.”

RBMG’s Managing Director, Trevor Brucato, stated:

“We are very proud and protective of our track record with our clients globally. RBMG partners with companies that meet our criteria and appear to be set up for long-term success. My team and I look forward to working with the Medibio team and introducing the Company and its disruptive screening technology for mental health to a wider audience within the investment community throughout the United States.”



Looking at Mental Health Objectively

Medibio is a mental health technology company pioneering the use of artificial intelligence, deep-learning algorithms and neural network methodology to identify biological markers and patterns to aid in early detection and screening of mental health conditions.

THE PROBLEM

Current diagnostic tests rely on **clinical interviews with subjective interpretation**



OUR SOLUTION

Identify biomarkers and patterns based on the patient's own biological data to **objectively aid in the early detection and screening of mental health conditions**



WHY INVEST IN MEDIBIO?



FDA Program Underway

If successful, Medibio's solution will be one of the first objective screening tests for depression approved by the FDA (De Novo Application)



Targeting a Large Market

In 2019, national spending on mental health services totaled \$225 billion and accounted for 5.5% of all health spending* 26% of the US population suffer from a mental health condition in a given year.




Patent-Protected, Innovative Technology

Assessing mental state using overnight heart rate
Cost effective to administer
Scalable



Early Revenue Potential

Early revenue opportunity in the non-clinical market with Medibio's **LUCA** and **ilumen** mobile apps



BUSINESS UNITS

Significant revenue potential in each market

CLINICAL



MEB-001 Sleep Clinics

Primary care physicians and other specialists referring patients to sleep clinics for sleep disturbance and depression screening




MEB-002 Homes

Depression Screening in Home Sleep Environment

NON-CLINICAL



FOR CONSUMERS



FOR CORPORATES

MEB-001 Depression Testing in Sleep Clinics

STATUS: FINAL TRIAL TO VALIDATE MEB-001

The FDA, during the pre-submission meeting on 2nd February 2022 and subsequent discussions, has been very supportive of Medibio's objectives and complimentary of the Company's MEB-001 validation trial design.

The FDA has acknowledged that MEB-001 is novel and will likely pave the way for other research and products.

Medibio and the FDA are currently in communication to agree on end-points that remained outstanding within the 60 minutes allocated for the meeting.

In anticipation of agreement during March, Medibio has 17 sleep clinics in various stages of preparedness to launch the validation trial.



Medibio's vision is that everyone referred for a sleep study will also be simultaneously screened for a Major Depressive Episode using MEB-001.

MEB-002 Depression Testing in the Home

More and more sleep studies are being performed in the patient's own home as opposed to in sleep clinics due to technological advancements, reduced cost and convenience.

In recognition of the growing patient cohort moving from in-clinic sleep studies to the home environment, **planning has now begun for the development of MEB-002**, which will screen for depression in patients undertaking a sleep study in the home environment.

MEB-002 algorithms will build on the success of MEB-001



MEB-001
CLINICAL TRIAL PARTNER



MedBridge is the leading provider of sleep laboratory management services in the United States, operating 140 sleep disorder diagnostic centres.

“The objective identification of depression in patients that suffer certain sleep disorders is an unmet need and we are pleased to be working with Medibio to fast-track patient recruitment in the validation trial.”

John Mathias - Chief Development Officer of MedBridge

CONSUMER HEALTH
LUCA Mobile App




Biometric-driven stress monitoring with **psychologist-developed tools** to help users understand and track stress to avoid more serious conditions.




BIOMETRICS

Tracking three components of physiological stress: Cardiac (HR), Activity, and Sleep along with an Overall Stress score



PERCEIVED STRESS ASSESSMENT

A short series of questions to determine a user's level of perceived stress



ODYSSEY

Tools and exercises to confront negative thinking patterns and identify stressors

LUCA + NORTHERN MICHIGAN UNIVERSITY (NMU) TRIAL PARTNER

- **Partnership:** Medibio and The Department of Neuroscience at NMU
- **Purpose:** Raise awareness of the LUCA app prevention tool amongst the student body to potentially help students avoid getting into the red zone and/or taking more drastic options such as dialing 911
- **Trial:** Medibio will engage the student body through a call-to-action event with impactful head-line spokespersons.
 - Based upon the success of this program, Medibio will look to scale this program across the US - a potential market of 20 million students and 4,000 schools and universities.
 - Medibio will collaborate with commercial partners and wearable device companies to participate in this worthwhile initiative.



Principal Investigators:

- Professor Adam Prus (Distinguished Professor & Head of Psychological Science NMU)
- Professor Joshua Carlson
- Assistant Professor Dr. Lin Fang

CORPORATE HEALTH
ilumen Mobile App




Provides the employer a dashboard of de-identified, aggregated data to better manage the mental wellbeing of their most important asset.....its workforce



CLOSES THE LOOP

Employers can now assess the effectiveness of employee wellness programs



FOR EMPLOYEES

Daily assessments on mobile or desktop



FOR EMPLOYERS

Dynamic view of their workforce

- Geographic locations
- Demographic data

REVENUE MODELS



MEB-001 & MEB-002

Licensing + Royalty Revenue



Consumer Health App

Free download + paid subscription model



Corporate Health App

Enterprise license based on a corporation's total workforce

LOOKING FORWARD
2022 DEVELOPMENT PROGRAM

		2021	H1 2022	H2 2022
CLINICAL	MEB-001 Depression Screening in Sleep Clinics	Development <ul style="list-style-type: none"> ✓ Sleep Algorithms ✓ Heart Rate Variability Algorithms ✓ Depression Analysis Algorithms 	Feasibility Trials	Complete FDA Validation Trial and submit the De Novo application.
	MEB-002 Depression Screening in the Home	<ul style="list-style-type: none"> ✓ Algorithm development ✓ Trial planning and design 	Feasibility Trials Trial will compare wearable devices to FDA approved medical devices	
NON-CLINICAL	ilumen App Corporate Market	✓ Launched in Australia	Market Feasibility	Potential Launch in USA
	LUCA App Consumer Market	<ul style="list-style-type: none"> ✓ App development ✓ Soft launch in October 2021 	<ul style="list-style-type: none"> • Planning for launch in college market • Pilot study for launch in college market 	Expand college market initiative to an initial 3 to 4 colleges across USA

THE TEAM


EXECUTIVE MANAGEMENT



CLAUDE SOLITARIO
Managing Director & Founder



ARCHIE DEFILLO
Chief Medical Officer



MASSIMILIANO GRASSI
Head of Artificial Intelligence



ZORIAN FEDORYGA
Head of Software Development



MARK WALINSKI
Business Development (North America)

BOARD OF DIRECTORS



CLAUDE SOLITARIO
Managing Director & Founder



MELANIE LEYDIN
*Non-Executive Director (CA, FGIA)
Managing Director - Vista Australia*



PETER CARLISLE
*Managing Director -
Olympics & Action Sports at
Octagon Worldwide*



MATT MESNIK M.D.
*Non-Executive Director
Chief Medical Officer - Spok Inc.*



STEPHEN MITCHLEY
*Non-Executive Director
CSO - Vitality Group (USA)*

ADVISORY BOARD



PETER CARLISLE
*Managing Director -
Olympics & Action Sports at
Octagon Worldwide*



ELIZABETH LOMBARDO, PhD
*Global & Virtual Keynote
Speaker and Author*



JOHN MATHIAS
*Chief Development Officer
MedBridge Healthcare*



MICHAEL PHELPS
Mental Health Advocate



PATRICK KENNEDY
*Former US Congressman
Founder, Kennedy Forum*

CONTACT US

medibio

www.medibio.com.au

Melbourne

Level 4, 100 Albert Road
South Melbourne, VIC 3205

United States HQ

8696 Eagle Creek Circle
Savage, MN 55378

Investor Relations

RB Milestone Group LLC (RBMG)
New York & Connecticut, United States
medibio@rbmilestone.com